Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.

Respir Res · 2017 · PMC5702233 · PMID 29178871

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

MORACTO 1 & 2 trials showed a trend over increased endurance time for TIO/OLO compared to TIO (MD 8.06 [−13.76 to 29.87], I 2 = 99%) or OLO (MD 23.67 [−21.34 to 68.69], I 2 = 100%); however, these results are limited by the significant heterogeneity between the two included trials.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.